Last edition
News about "Phase 2 clinical trial"
Akeso Initiates Phase 2 Trial of TROP2/Nectin-4 Bispecific ADC in Advanced Breast Cancer
Akeso has dosed the first patient in a Phase 2 study of AK146D1 combined with ivonescimab, advancing its next-generation “IO2.0 + ADC2.0” approach for advanced breast cancer.
Phase 2 Clinical Trial | 10/08/2026 | By News Bureau
Innovent Biologics Licenses Anti-CD40L Therapy IBI355 to Spero Therapeutics in USD 1.1 Billion Deal
Innovent Biologics has licensed global rights outside Greater China for its anti-CD40L antibody IBI355 to Spero Therapeutics in a deal valued at up to USD 1.1 billion, advancing the development of a potential new treatment for autoimmune diseases including IgG4-related disease and Sjögren's disease.
Phase 2 Clinical Trial | 15/07/2026 | By News Bureau | 188
TG Therapeutics Launches Phase 2 Trial of BRIUMVI for Schizophrenia
TG Therapeutics has initiated a Phase 2 trial of BRIUMVI in treatment-resistant schizophrenia, evaluating B-cell depletion as a potential therapy for patients with immune dysfunction.
Phase 2 Clinical Trial | 07/07/2026 | By News Bureau | 143
NeuroSense Reports Positive Phase 2 Biomarker Results for PrimeC in Alzheimer's Disease Trial
PrimeC shows encouraging biomarker activity in Phase 2 Alzheimer’s study, supporting its potential as a multi-target therapy for neurodegenerative diseases.
Phase 2 Clinical Trial | 26/06/2026 | By News Bureau | 200
Hengrui Pharma and Braveheart Bio have reported positive Phase 2 clinical trial results for investigational cardiac therapy HRS/BHB-1893 in patients with non-obstructive hypertrophic cardiomyopathy, demonstrating improvements in cardiac function, biomarkers and patient outcomes.
Phase 2 Clinical Trial | 12/05/2026 | By News Bureau | 287
Hope Medicine Reports Positive Phase II Results for First-in-Class Endometriosis Drug
HMI-115 shows significant pain reduction without hormonal disruption, paving the way for global phase III trials.
Phase 2 Clinical Trial | 26/03/2026 | By News Bureau | 292
Inimmune Begins Phase 2 Trial of INI-2004 for Allergic Rhinitis
The randomised, placebo-controlled allergen chamber study will evaluate the safety and efficacy of Inimmune’s immunotherapy candidate INI-2004 in patients exposed to controlled ragweed allergens.
Phase 2 Clinical Trial | 08/01/2026 | By News Bureau | 271
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy